Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of CV9104 RNActive cancer vaccine in intermediate- and high-risk prostate cancer
2013-004489-32Phase 2Terminated
- Sponsor
- CureVac
- Start
- Dec 2013
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of CV9104 in prostate cancer (PCa) (3 arms), sponsored by CureVac. Primary endpoint: Induction of antigen-specific cellular and humoral immune response. Started Dec 2013; status: terminated.
02
Drugs
CV9104
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2013-004489-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004489-32.